Get the Stockscreener App
0.00
100.00%
-53.01
Soleno Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.
See More
Previous Close:
$53.01
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$2.76B
Revenue:
$285.01M
Net Income/Loss:
$95.63M
P/E Ratio:
0.00
EPS:
1.762
Net Cash Flow:
$105.42M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
0.00 | 2.76B | 285.01M | 95.63M | 105.42M | 1.762 |
VRTX
Vertex Pharmaceuticals Inc
|
437.68 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.93 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.73 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.73 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.60 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-07-25 | Initiated | Goldman | Buy |
| Aug-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Soleno Therapeutics (NASDAQ: SLNO) deregisters 3,000,000-share resale after merger - Stock Titan
News On Soleno Therapeutics Inc. (SLNO) Now Under NBIX - Moomoo
Soleno Therapeutics, Inc.(NasdaqGM: ) dropped from Russell 3000E Index - marketscreener.com
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - Sahm
Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics - Moomoo
Merger cashes out Soleno (NASDAQ: SLNO) officer equity at $53 - Stock Titan
Soleno Therapeutics (SLNO) director’s shares and options cancelled for $53 cash in Neurocrine merger - Stock Titan
Soleno Therapeutics (SLNO) director equity canceled in $53-per-share merger - Stock Titan
Soleno (SLNO) director’s shares cashed out at $53 per-share merger price - Stock Titan
Soleno Therapeutics (SLNO) CBO equity canceled, cashed out at $53 per share - Stock Titan
Soleno Therapeutics (SLNO) CCO equity cancelled, converted to $53 cash in merger - Stock Titan
Soleno Therapeutics (SLNO) CDO equity cancelled for $53 cash in merger - Stock Titan
Soleno (SLNO) SVP exits equity as merger pays $53 per share - Stock Titan
Soleno Therapeutics (SLNO) insider equity cashed out at $53 in Neocrine merger - Stock Titan
Soleno (SLNO) director’s 10,046 RSUs canceled for $53 cash in merger - Stock Titan
Soleno Therapeutics (SLNO) CFO has RSUs and stock options cashed out in Neocrine merger - Stock Titan
Soleno Therapeutics (SLNO) director exits as $53-per-share cash merger closes - Stock Titan
Soleno Therapeutics (SLNO) CEO fully cashed out as $53-per-share merger closes - Stock Titan
Neurocrine Biosciences completes $2.9 billion Soleno acquisition - Investing.com UK
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others. - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics, Adds VYKAT XR for Prader-Willi Syndrome to Rare Disease Portfolio - Minichart
Soleno Therapeutics Announces Acquisition by Neurocrine Biosciences and Corporate Changes – SEC Form 8-K Filing - Minichart
Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq - Investing.com Nigeria
Neurocrine Closes $2.9 Billion Soleno Acquisition to Expand Rare Disease Portfolio - citybiz
Neurocrine Biosciences completes $2.9 billion Soleno acquisition By Investing.com - Investing.com Australia
Neurocrine Biosciences completes acquisition of Soleno Therapeutics - marketscreener.com
Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics - TradingView
Soleno Therapeutics (NASDAQ: SLNO) taken private at $53 per share in cash deal - Stock Titan
Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger - Stock Titan
Soleno Therapeutics (SLNO) Nasdaq submits Form 25 to remove common stock - Stock Titan
Soleno Therapeutics, Inc. Announces Resignation of Anish Bhatnagar, M.D. as Chief Executive Officer, Effective May 18, 2026 - marketscreener.com
Neurocrine Biosciences (NASDAQ: NBIX) completes $2.9B Soleno acquisition - Stock Titan
Neurocrine completes Soleno buyout (NASDAQ: SLNO) at $53.00 per share - Stock Titan
Neurocrine (SLNO) completes tender offer; ~46.36M Soleno shares tendered - Stock Titan
Press Release: Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - Moomoo
Soleno Therapeutics, Inc. (SLNO) Stock Report: A Biotech Player with Steady ROE and Strategic Focus on Rare Diseases - DirectorsTalk Interviews
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Soleno Therapeutics, Inc.(NasdaqCM: SLNO) dropped from S&P Global BMI Index - marketscreener.com
Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Soleno Therapeutics, Inc.(NasdaqCM: SLNO) dropped from S&P TMI Index - marketscreener.com
Soleno Therapeutics, Inc.(NasdaqGM: SLNO) dropped from NASDAQ Composite Index - marketscreener.com
The Technical Signals Behind (SLNO) That Institutions Follow - Stock Traders Daily
T. Rowe Price (NASDAQ: SLNO) reports 1,025,868 shares, 2.0% stake - Stock Titan
Avoro and Aghazadeh report 4.45% stake in Soleno (NASDAQ: SLNO) - Stock Titan
Wellington affiliates disclose 8.57% stake in Soleno Therapeutics (SLNO) - Stock Titan
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN
State Street (SLNO) holds 2.68M shares, 5.2% stake in Soleno Therapeutics - Stock Titan
SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch DisruptionsHagens Berman - PR Newswire
Soleno Therapeutics faces final earnings test before buyout By Investing.com - Investing.com South Africa
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Soleno Therapeutics Inc Stock (SLNO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Huang Michael F. | Sr. VP of Clinical Development |
Mar 27 '26 |
Sale |
30.44 |
6,582 |
200,365 |
39,823 |
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):